ClinicalTrials.gg
CompletedNCT07288970Updated Oct 19, 2026

ACB With S-ESPB Versus ACB With iPACK for Knee Arthroplasty

An interventional study of Adductor Canal Block and Sacral Erector Spinae Plane Block in Knee Osteoarthritis, sponsored by Poznan University of Medical Sciences. Completed at 1 site in Poland. Open to participants aged 65 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Poznan University of Medical Sciences · Not applicable, Interventional, and Treatment

How we know

Updated Oct 19, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
65 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Osteoarthritis, Knee by Poznan University of Medical Sciences — 2 open to participants now, 3 under way, none of them phase 3. Osteoarthritis, Knee · Poznan University of Medical Sciences.

Enrollment
8th of 13
80 · median 90
Started
2025
with 1 other
No phase
4 of 13
2 open now
Registered
10th of 13
by date

Among the 13 studies in Osteoarthritis, Knee by Poznan University of Medical Sciences, this one is the 8th largest by enrollment, is one of 2 that started in 2025, is one of 4 with no phase, and was the 10th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

2 of the 13 studies in Osteoarthritis, Knee by Poznan University of Medical Sciences are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 65 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Osteoarthritis, Knee by Poznan University of Medical Sciences, or all of them as a file.
02

Study summary

This study will compare two regional anesthesia strategies for pain management after total knee arthroplasty in adults. Both strategies use an adductor canal block (ACB) to provide analgesia while preserving quadriceps muscle strength. The ACB is then combined with either a sacral erector spinae plane block (S-ESPB) or an iPACK (infiltration between the popliteal artery and the posterior capsule of the knee) block to improve posterior knee analgesia.

All patients will receive an ultrasound-guided adductor canal block with 20 mL of 0.2% ropivacaine. They will then be randomly assigned to one of two groups:

Group 1: ACB combined with a sacral erector spinae plane block (S-ESPB) using 20 mL of 0.2% ropivacaine.

Group 2: ACB combined with an iPACK block using 20 mL of 0.2% ropivacaine. Both techniques aim to provide effective postoperative analgesia while minimizing motor blockade and allowing for early mobilization. It is not known whether combining ACB with S-ESPB or with iPACK provides superior pain control, reduces opioid requirements, or results in better functional recovery after total knee arthroplasty.

The main purpose of this study is to compare the time to first rescue analgesia and overall postoperative pain control between the two regional anesthesia strategies. The study will also evaluate opioid consumption, motor function, functional mobility, side effects, and block-related complications.

We hypothesize that both combinations will provide effective analgesia, but their impact on pain intensity, duration of analgesia, and functional recovery may differ.

Read the detailed description

Total knee arthroplasty (TKA) is associated with significant postoperative pain, which can limit early mobilization, delay rehabilitation, and increase opioid use. Inadequate pain control may lead to complications such as decreased range of motion, prolonged hospitalization, and reduced patient satisfaction. Regional anesthesia techniques are a cornerstone of multimodal analgesia protocols for TKA.

The adductor canal block (ACB) is a motor-sparing technique that targets the saphenous nerve and nerve to vastus medialis while largely preserving quadriceps strength. However, ACB alone may not provide sufficient analgesia for posterior knee structures. To address this limitation, it is often combined with other blocks that target posterior knee innervation.

The iPACK (infiltration between the popliteal artery and the posterior capsule of the knee) block is designed to anesthetize the articular branches supplying the posterior capsule of the knee without causing significant motor block. The sacral erector spinae plane block (S-ESPB) is a more proximal truncal block, which may provide analgesia to the posterior knee and surrounding structures through spread of local anesthetic in the fascial planes.

This randomized controlled trial will compare two regional anesthesia strategies in patients undergoing total knee arthroplasty:

Adductor canal block (ACB) combined with sacral erector spinae plane block (S-ESPB).

Adductor canal block (ACB) combined with iPACK block. In both groups, 20 mL of 0.2% ropivacaine will be used for each block (ACB + S-ESPB or ACB + iPACK). All patients will receive standard perioperative care and multimodal analgesia according to institutional protocols.

The primary outcome of the study is the time to first rescue analgesia within 48 hours after surgery. Secondary outcomes include pain intensity at rest and during movement, total opioid consumption, motor function (quadriceps strength), postoperative nausea and vomiting, hemodynamic events, block-related complications, time to first mobilization, and patient satisfaction with pain management.

The study aims to determine whether combining ACB with S-ESPB or with iPACK results in better analgesia and functional outcomes after TKA. The results may help optimize regional anesthesia protocols for total knee arthroplasty and improve postoperative recovery.

03

Conditions studied

  • Knee Osteoarthritis
04

Who can participate

Ages eligible
65 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 65 years or older
  • Scheduled for elective unilateral total knee arthroplasty under spinal or general anesthesia
  • I-III
  • Planned use of regional anesthesia with an adductor canal block as part of multimodal analgesia
  • Ability to communicate pain intensity using the NRS scale
  • Written obtained from the patient

Exclusion criteria

Exclusion Criteria:

  • Refusal or inability to provide
  • Allergy, intolerance, or to local anesthetics (ropivacaine)
  • Pre-existing significant neurological deficit or neuropathy in the operative limb
  • Coagulopathy or anticoagulation that contraindicates peripheral nerve blocks (e.g., >1.5, \<100,000/µL, or therapeutic anticoagulation that cannot be safely paused)
  • Infection at or near the planned needle insertion sites
  • Severe hepatic or renal impairment
  • Chronic opioid therapy (>30 days of daily opioid use before surgery)
  • Cognitive impairment or delirium preventing reliable pain assessment > 40 kg/m² (optional - if chcesz ograniczyć ze względu na trudność USG)
  • Previous knee arthroplasty on the same side or revision TKA (jeśli chcesz tylko primary TKA)
  • Pregnancy or breastfeeding
  • Participation in another interventional clinical trial within 30 days
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (actual)

Study arms

  • Active comparator
    Adductor Canal Block Plus Sacral Erector Spinae Plane Block (ACB + S-ESPB)

    Participants will receive an ultrasound-guided adductor canal block with 20 mL of 0.2% ropivacaine and a sacral erector spinae plane block with 20 mL of 0.2% ropivacaine. All patients will receive standard perioperative care and multimodal analgesia.

    Procedure: Adductor Canal Block · Procedure: Sacral Erector Spinae Plane Block

  • Active comparator
    Adductor Canal Block Plus iPACK Block (ACB + iPACK)

    Participants will receive an ultrasound-guided adductor canal block with 20 mL of 0.2% ropivacaine and an iPACK block with 20 mL of 0.2% ropivacaine. All patients will receive standard perioperative care and multimodal analgesia.

    Procedure: Adductor Canal Block · Procedure: iPACK Block

Interventions

  • ProcedureAdductor Canal Block

    Ultrasound-guided adductor canal block performed with 20 mL of 0.2% ropivacaine injected around the saphenous nerve within the adductor canal. Used in both study arms as part of the regional anesthesia protocol for total knee arthroplasty.

    Also known as: ACB

  • ProcedureSacral Erector Spinae Plane Block

    Ultrasound-guided sacral erector spinae plane block performed with 20 mL of 0.2% ropivacaine injected deep to the erector spinae muscle at the sacral level. Used in combination with ACB in the ACB + S-ESPB group.

    Also known as: S-ESPB; Sacral ESP block

  • ProcedureiPACK Block

    Ultrasound-guided iPACK block performed with 20 mL of 0.2% ropivacaine injected between the popliteal artery and the posterior capsule of the knee. Used in combination with ACB in the ACB + iPACK group.

    Also known as: Infiltration between the popliteal artery and the posterior capsule of the knee

06

What researchers measure

Primary outcomes

  1. Time to First Rescue Analgesia

    Time (in hours) from completion of the regional blocks to the first administration of a rescue analgesic (opioid or non-opioid) given for pain intensity ≥4 on the 0-10 Numerical Rating Scale (NRS).

    Time frame: Within 48 hours after surgery.

Secondary outcomes

  1. Pain Intensity at Rest (NRS 0-10)

    Pain at rest measured using the 0-10 NRS (0 = no pain, 10 = worst imaginable pain). Mean values will be compared between groups.

    Time frame: 4 hours after surgery.

  2. Pain Intensity at Rest (NRS 0-10)

    Pain at rest measured using the 0-10 NRS (0 = no pain, 10 = worst imaginable pain). Mean values will be compared between groups.

    Time frame: 8 hours after surgery.

  3. Pain Intensity at Rest (NRS 0-10)

    Pain at rest measured using the 0-10 NRS (0 = no pain, 10 = worst imaginable pain). Mean values will be compared between groups.

    Time frame: 12 hours after surgery.

  4. Pain Intensity at Rest (NRS 0-10)

    Pain at rest measured using the 0-10 NRS (0 = no pain, 10 = worst imaginable pain). Mean values will be compared between groups.

    Time frame: 24 hours after surgery.

  5. Pain Intensity at Rest (NRS 0-10)

    Pain at rest measured using the 0-10 NRS (0 = no pain, 10 = worst imaginable pain). Mean values will be compared between groups.

    Time frame: 48 hours after surgery.

  6. Pain Intensity During Movement (NRS 0-10)

    Pain during standardized knee movement (e.g., flexion or assisted mobilization) measured using the 0-10 NRS.

    Time frame: 4 hours after surgery.

  7. Pain Intensity During Movement (NRS 0-10)

    Pain during standardized knee movement (e.g., flexion or assisted mobilization) measured using the 0-10 NRS.

    Time frame: 8 hours after surgery.

  8. Pain Intensity During Movement (NRS 0-10)

    Pain during standardized knee movement (e.g., flexion or assisted mobilization) measured using the 0-10 NRS.

    Time frame: 12 hours after surgery.

  9. Pain Intensity During Movement (NRS 0-10)

    Pain during standardized knee movement (e.g., flexion or assisted mobilization) measured using the 0-10 NRS.

    Time frame: 24 hours after surgery.

  10. Pain Intensity During Movement (NRS 0-10)

    Pain during standardized knee movement (e.g., flexion or assisted mobilization) measured using the 0-10 NRS.

    Time frame: 48 hours after surgery.

  11. Total Opioid Consumption

    Cumulative dose of opioids converted to oral morphine milligram equivalents (MME).

    Time frame: 0-48 hours after surgery.

  12. Motor Function (Quadriceps Strength, MRC Scale)

    Quadriceps muscle strength assessed using the Medical Research Council (MRC) scale (0 = no contraction; 5 = normal power) to detect any motor impairment associated with the regional anesthesia techniques.

    Time frame: 4 hours after surgery.

  13. Motor Function (Quadriceps Strength, MRC Scale)

    Quadriceps muscle strength assessed using the Medical Research Council (MRC) scale (0 = no contraction; 5 = normal power) to detect any motor impairment associated with the regional anesthesia techniques.

    Time frame: 8 hours after surgery.

  14. Motor Function (Quadriceps Strength, MRC Scale)

    Quadriceps muscle strength assessed using the Medical Research Council (MRC) scale (0 = no contraction; 5 = normal power) to detect any motor impairment associated with the regional anesthesia techniques.

    Time frame: 12 hours after surgery.

  15. Motor Function (Quadriceps Strength, MRC Scale)

    Quadriceps muscle strength assessed using the Medical Research Council (MRC) scale (0 = no contraction; 5 = normal power) to detect any motor impairment associated with the regional anesthesia techniques.

    Time frame: 24 hours after surgery.

  16. Motor Function (Quadriceps Strength, MRC Scale)

    Quadriceps muscle strength assessed using the Medical Research Council (MRC) scale (0 = no contraction; 5 = normal power) to detect any motor impairment associated with the regional anesthesia techniques.

    Time frame: 48 hours after surgery.

  17. Incidence of Postoperative Nausea and Vomiting (PONV)

    Presence of nausea or vomiting requiring antiemetic therapy. Proportion of patients with at least one episode will be recorded.

    Time frame: 0-48 hours after surgery.

  18. Hemodynamic Adverse Events

    Incidence of hypotension (systolic BP \<90 mmHg or \>30% decrease from baseline) and bradycardia (HR \<50/min) requiring treatment.

    Time frame: From block placement until 24 hours after surgery.

  19. Block-Related Adverse Events

    Incidence of complications related to the regional blocks, including prolonged sensory or motor deficit, nerve injury (evaluated in outpatient clinic if required), hematoma, infection at the injection site, persistent weakness, or local anesthetic systemic toxicity.

    Time frame: From block placement until 30 days after surgery.

07

Study locations

1 site
  • Poznan University of Medical Sciences
    Poznan, 62-701, Poland
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: 12 months after publication, available for 5 years

Access criteria: upon reasonable request; de-identified data; DSA if needed

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2025 to primary completion in Sep 2026, 8 months.

Of 1,114 non-industry interventional studies with no phase under Osteoarthritis, Knee, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's 8 months is below that.

Counting every sponsor, half of 1,253 studies reached it within 18 months; a quarter within 8 and three quarters within 36.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 19, 2026: primary completion Jan 2027 → Sep 2026 and completion Jan 2027 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2025
First posted
Dec 17, 2025
StartActual
Dec 25, 2025
Primary completionActual
Sep 4, 2026was Jan 2027
CompletionActual
Oct 4, 2026was Jan 2027
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 19, 2026
Primary completion
Jan 1, 2027→Sep 4, 2026 (actual)
Oct 19, 2026
Study completion
Jan 31, 2027→Oct 4, 2026 (actual)
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Recruiting→Completed
    Primary completion Jan 1, 2027→Sep 4, 2026 (now actual)
    Study completion Jan 31, 2027→Oct 4, 2026 (now actual)
    + 2 other changes: contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07288970
Responsible party
Sponsor
First posted
Dec 17, 2025
Start date
Dec 25, 2025
Primary completion
Sep 4, 2026
Completion
Oct 4, 2026
Last update
Oct 19, 2026

Study contacts

Malgorzata Reysner, MD PhD
study chair · Poznan University of Medical Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion